France OKs Early Access To Tecentriq For SCLC Pending EU Approval

 
• By Ian Schofield

Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.

XRay
France is making Tecentriq available for small cell lung cancer • Source: Shutterstock

More from Market Access

More from Pink Sheet